Lithium for Health & Longevity

Evidence Review created on 08/08/2026 using AI4L / Opus 5

Also known as: Lithium Orotate, Lithium Carbonate, Lithium Citrate, Lithium Aspartate, Lithium Chloride, Li

Motivation

Lithium is the lightest metal and a naturally occurring trace element found in soil, drinking water, and many plant foods. Most people encounter it as a mood-stabilizing medication prescribed in large amounts for bipolar disorder. Far smaller quantities — the amounts present in ordinary food and sold over the counter — have drawn a separate kind of interest, as something closer to a nutrient for the aging brain.

Lithium was used medicinally long before modern psychiatry existed. Nineteenth-century spa waters and early soft drinks were sold partly for the lithium they contained. More recently, regions whose water carries more of it have been reported to record fewer deaths and fewer dementia diagnoses than regions where it is scarce, and simple laboratory organisms given tiny amounts have lived longer.

This review examines lithium across its full range of use, from trace dietary intake to prescription therapy. It sets out how the metal acts in the body, which benefits and which harms the evidence supports at each level of exposure, how it is dosed, sourced, and monitored, and where the limits of current knowledge lie.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Lithium (medication)

Covers lithium as a therapeutic agent rather than as an industrial metal, including its pharmacology, dosing conventions, and adverse-effect profile. It is the most complete single reference page for the prescription side of the topic, though it gives little space to trace-dose or nutritional use.

Examine

No dedicated Examine article on lithium exists. The site carries only individual study summaries in its research feed — one on lithium in public water and suicide rates, one (since retracted) on lithium and longevity in affective disorders — and a passing mention of lithium in a pregnancy safety guide. None of these is a primary, dedicated page for the intervention.

Lithium carbonate is a prescription medication in every major market, and Examine’s supplement database does not generally cover prescription medications, which is the most likely reason no monograph exists despite lithium orotate being widely sold over the counter.

ConsumerLab

Low-Dose Lithium Supplements Review

Reports independent testing of retail lithium products for actual lithium content and for lead, cadmium, and arsenic contamination, and flags the labeling trap in which a stated milligram figure refers to the whole compound rather than the lithium in it. ConsumerLab earns revenue from subscriptions rather than from supplement sales, so it has no direct financial stake in the products it grades.

Systematic Reviews

The following systematic reviews and meta-analyses cover lithium’s effects on cognition, dementia risk, population health outcomes, and its toxicity profile.

Identifying the neuropsychiatric health effects of low-dose lithium interventions: A systematic review - Strawbridge et al., 2023

The only synthesis restricted to interventional studies of sub-therapeutic lithium, defined as a serum level at or below 0.6 mmol/L. Across eighteen studies it found signals for attenuating cognitive decline and for augmenting treatment of depression and mania, with a consistently benign safety record, while noting that the underlying studies are few and highly heterogeneous.
Lithium and disease modification: A systematic review and meta-analysis in Alzheimer’s and Parkinson’s disease - Singulani et al., 2024

Pools thirty-two studies, of which twenty-nine were in animals, and reports reduced amyloid-beta and tau levels (the two proteins whose brain deposits define Alzheimer’s disease) with improved cognitive behavior in Alzheimer’s models, plus increased tyrosine hydroxylase (the enzyme that performs the first step in making dopamine) and better motor behavior in a Parkinson’s model. Its own structure is the clearest available illustration of how heavily this field still rests on preclinical work.
Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis - Huang et al., 2024

Pools eight observational studies covering 377,060 people and finds no significant association between lithium use and dementia risk, including when the analysis is restricted to bipolar disorder to reduce confounding by indication (the illusion created when the people who receive a treatment differ systematically from those who do not). It is the strongest published counterweight to the protective-effect literature.
The association between lithium in drinking water and neuropsychiatric outcomes: A systematic review and meta-analysis from across 2678 regions containing 113 million people - Eyre-Watt et al., 2021

The largest synthesis of the drinking-water literature, reporting an inverse association between water lithium and suicide rates across fourteen studies covering 94 million people. It also reports substantial between-study heterogeneity and a positive test for publication bias (the tendency for studies finding an effect to be published more readily than those that do not), which is essential context for the frequently quoted headline.
Lithium toxicity profile: a systematic review and meta-analysis - McKnight et al., 2012

Screened 5,988 abstracts and analyzed 385 studies to produce the reference quantification of lithium’s harms at therapeutic doses, covering renal, thyroid, and parathyroid function, weight, skin, hair, and teratogenicity (the capacity of a substance to cause birth defects). Nearly every risk figure quoted in the modern lithium literature traces back to this paper.

Mechanism of Action

Lithium has no single receptor. It is a small positively charged ion that competes with magnesium at the binding sites of several enzymes and partially substitutes for sodium in cellular transport, which is why it touches many systems at once rather than one cleanly.

GSK-3β inhibition: GSK-3β (glycogen synthase kinase-3 beta, an enzyme that switches other proteins on and off by attaching phosphate groups to them) is the most cited target. Lithium blocks it in two ways: directly, by displacing magnesium from the enzyme’s active site, and indirectly, by promoting an inhibitory modification of the enzyme itself. Because GSK-3β adds phosphate groups to tau (the protein whose tangles are one of the two defining lesions of Alzheimer’s disease), inhibiting it is the mechanistic basis for most neuroprotection claims. GSK-3α (the closely related sibling enzyme) influences the processing of amyloid precursor protein into amyloid-beta, the other defining lesion.
Inositol depletion: Lithium inhibits inositol monophosphatase and inositol polyphosphate 1-phosphatase, two enzymes that recycle inositol (a sugar-like molecule that cells need to build the signaling messengers used by many hormone and neurotransmitter receptors). Draining that pool dampens overactive signaling. This is the older of the two dominant mechanistic accounts and remains the leading explanation for the mood-stabilizing effect specifically.
Autophagy induction: Inositol depletion also triggers autophagy (the cell’s process for digesting and recycling its own damaged components) through a route that does not involve mTOR (mechanistic target of rapamycin, the master growth-signaling hub that most other autophagy-inducing interventions work through). This independence is why lithium is sometimes discussed as combinable with rapamycin-like agents rather than redundant with them.
Neurotrophic and anti-apoptotic signaling: Chronic lithium exposure raises BDNF (brain-derived neurotrophic factor, a protein that supports the survival and growth of neurons) and Bcl-2 (B-cell lymphoma 2, a protein that blocks cells from triggering their own death). Human imaging studies have found higher N-acetylaspartate (a chemical marker of neuronal viability) and preserved gray matter in the hippocampus and the surrounding emotion-regulating regions, as summarized by Moore et al., 2026 — a narrative review whose authors include affiliations with Gates Ventures and the Alzheimer’s Disease Data Initiative, both of which fund work in this area.
Antioxidant and hormetic signaling: In fruit flies, lifespan extension by lithium required both GSK-3 inhibition and activation of NRF2 (nuclear factor erythroid 2-related factor 2, the transcription factor that switches on a cell’s antioxidant defenses), and followed a hormetic dose-response in which low amounts extended life and high amounts shortened it (Castillo-Quan et al., 2016). This is the clearest mechanistic argument that lithium’s longevity effect, if real, is a low-dose phenomenon rather than a scaled-down version of the psychiatric effect.
Competing mechanistic accounts — the trace-element hypothesis: Aron et al., 2025 reported that of the metals measured in post-mortem human brain, lithium alone was significantly reduced in mild cognitive impairment (the stage of measurable memory loss that precedes dementia), that amyloid sequesters lithium and further reduces its availability, and that cutting endogenous cortical lithium by roughly half in mice increased amyloid-beta deposition, phospho-tau accumulation, inflammatory activation of microglia (the brain’s resident immune cells), and loss of synapses, axons, and myelin (the insulating sheath around nerve fibers). On this account lithium is a physiological requirement whose loss helps initiate the disease, rather than a drug that happens to help — a materially different claim, with different implications for who would benefit.
Competing mechanistic accounts — does the salt matter?: Pacholko & Bekar, 2021 and Pacholko & Bekar, 2023 argue that lithium orotate crosses the blood-brain barrier and enters cells more readily than lithium carbonate, allowing lower doses and a wider safety margin. Hajek et al., 2026 contest this on chemical grounds: no study has demonstrated stable lithium orotate in physiological fluids, acid-base chemistry predicts the salt dissociates in the stomach and is absorbed as free lithium ion, and comparative studies show similar pharmacokinetics for the two salts. This dispute is unresolved and directly determines whether the supplement market’s preferred form has any advantage at all.
Key pharmacological properties: Elimination half-life is roughly 18 to 36 hours, extending toward the upper end and beyond in older adults and in reduced kidney function. Lithium is not bound to plasma proteins, is not metabolized at all — it passes through none of the cytochrome P450 enzymes such as CYP3A4 (the liver enzyme family that chemically breaks down most medications), and has no active metabolite — and is cleared almost entirely by the kidney, where about 80% of the filtered load is reabsorbed in the proximal tubule in competition with sodium. Its volume of distribution of roughly 0.7 to 1.0 L/kg approximates total body water, so it is not selective for any tissue; it enters brain more slowly than plasma and leaves more slowly, which is why brain and serum levels can diverge. Direct measurement in humans given 5 mg of lithium orotate daily found detectable brain concentrations in the range of approximately 10 to 60 mM (Neal et al., 2024).

Historical Context & Evolution

Original medical use — gout, not mood: Lithium entered medicine in 1859, when Alfred Baring Garrod proposed lithium carbonate for gout on the reasoning that lithium urate was the most soluble urate salt he could make in a test tube and would therefore dissolve the deposits causing the disease. The chemistry was correct in vitro. The concentrations required were never achievable in living tissue, and the treatment did not work for the reason proposed — but the idea drove a lithia-water industry, and the resulting spa waters and mineral springs delivered trace lithium to large populations for decades.
Lithium in the beverage supply: Bib-Label Lithiated Lemon-Lime Soda, launched in 1929 and later renamed 7 Up, contained lithium citrate until its removal in 1948. This is usually retold as a curiosity, but the actual finding matters for the modern trace-dose argument: a widely consumed beverage delivered supplemental lithium at sub-psychiatric amounts for two decades without a recognized pattern of harm.
The salt-substitute disaster: In the 1940s lithium chloride was marketed as a sodium-free table salt for patients on low-sodium cardiac diets. Several deaths and many severe poisonings followed, and the U.S. Food and Drug Administration banned it in 1949. The actual findings here are specific rather than general: the harm came from unrestricted intake of gram quantities in exactly the population — sodium-depleted cardiac patients — whose kidneys reabsorb lithium most avidly. The episode is evidence about dose and about renal handling; it is not evidence that trace exposure is dangerous, and it is not evidence that gram-scale exposure is safe.
Cade’s observation and Schou’s trials: In 1949 John Cade, investigating whether a toxin in the urine of manic patients caused the illness, injected guinea pigs with lithium urate as a solubility vehicle and observed that the animals became placid. He then gave lithium to ten manic patients and reported marked improvement. The observation was uncontrolled and the guinea-pig reasoning was wrong, but the clinical claim survived testing: Mogens Schou’s placebo-controlled trials through the 1950s and 1960s confirmed both acute and preventive effects, and the U.S. Food and Drug Administration approved lithium in 1970.
The trace-element line of research: From the 1970s, work by Earl Dawson and later Gerhard Schrauzer examined lithium in Texas drinking water against county rates of suicide, homicide, and arrest, reporting inverse associations, and led Schrauzer to propose a provisional daily requirement of roughly 1 mg for a 70 kg adult. These are ecological analyses comparing places rather than people, and cannot separate lithium from everything else that differs between counties. That is a real limitation of the design, not a refutation of the finding, and later work in Denmark and Japan using individual-level exposure assignment reached compatible conclusions while the largest pooled analysis found publication bias in the same literature.
How opinion has moved, and why: For most of the modern era the professional position treated lithium as a narrow-window psychiatric drug and trace-lithium research as fringe. Two things changed that. First, the mechanistic overlap between GSK-3β and Alzheimer’s pathology gave a plausible reason for a non-psychiatric effect. Second, Aron et al., 2025 supplied direct human measurements of brain lithium depletion in early disease. New evidence has also arrived on the skeptical side: the pilot randomized trial Gildengers et al., 2026 missed all six of its co-primary endpoints, and a pooled analysis of observational data found no dementia association at all (Huang et al., 2024). Neither camp’s position is currently the settled one.

Expected Benefits

High 🟩 🟩 🟩

Prevention of Recurrence in Bipolar Disorder

Lithium prevents the return of manic and depressive episodes and remains the reference standard against which every newer mood stabilizer is measured, supported by decades of randomized controlled trials (studies in which participants are assigned to treatment or comparison purely by chance) and multiple network meta-analyses (pooled analyses that also rank treatments never compared head to head). For a health-optimizing audience without a mood disorder this benefit is not personally applicable, but it matters as calibration: this is the only lithium effect where the evidence is unambiguous, and it was obtained at blood concentrations five to ten times those produced by supplement doses. Any claim that trace lithium delivers a scaled-down version of this effect is an extrapolation, not an observation.

Magnitude: Roughly a 30–40% relative reduction in mood-episode recurrence versus placebo over 12–24 months, at serum levels of 0.6–1.0 mmol/L.

Reduced Suicide and All-Cause Death in Mood Disorders

Among people with unipolar or bipolar mood disorders, lithium reduces both completed suicide and death from any cause, an effect that appears larger than what relapse prevention alone would predict and is thought to involve independent reductions in aggression and impulsivity. The meta-analysis by Cipriani et al., 2013 pooled 48 randomized trials and 6,674 participants, reporting the result as an odds ratio (a number comparing how often an event happens in one group versus another, where 1 means no difference and below 1 means less often) with a 95% confidence interval (the range within which the true value most plausibly lies). Those intervals are wide because suicide is a rare event even in this population, and the finding does not transfer to people without a mood disorder.

Magnitude: Odds ratio 0.13 (95% confidence interval 0.03–0.66) for suicide and 0.38 (0.15–0.95) for death from any cause versus placebo.

Medium 🟩 🟩

Slower Cognitive Decline in Mild Cognitive Impairment ⚠️ Conflicted

Mild cognitive impairment is the state at which most health- and longevity-focused individuals would first consider lithium. Two small randomized trials from the same São Paulo group found that sub-therapeutic lithium, targeted to 0.25–0.5 mmol/L, slowed cognitive and functional decline over one and two years and reduced phospho-tau in cerebrospinal fluid (the fluid bathing the brain and spinal cord) (Forlenza et al., 2011; Forlenza et al., 2019). The larger and better-instrumented Gildengers et al., 2026 pilot trial missed all six co-primary endpoints, including hippocampal volume and cortical gray matter volume. The evidence is directly conflicted: the verbal-memory measure in that trial moved in the predicted direction and would have been called positive on a single-endpoint design, while the imaging measures showed nothing at all, and the São Paulo trials were small enough that chance remains a live explanation.

Magnitude: In the 2026 trial, word-list recall declined 1.42 points per year on placebo versus 0.73 on lithium (difference 0.69 points per year, 95% confidence interval 0.01–1.37); in the 2019 trial, the placebo group declined while the lithium group remained stable over two years.

Lower Dementia Incidence with Long-Term Exposure ⚠️ Conflicted

Population studies have repeatedly found that people with more lithium exposure — whether from prescriptions or from drinking water — are diagnosed with dementia less often. The Danish national study by Kessing et al., 2017 linked individual residential histories to water measurements across 73,731 dementia cases and 733,653 matched controls. Evidence is conflicted at the level of pooled analyses: Lu et al., 2024 found a clear protective association across seven studies, while Huang et al., 2024 found none across eight covering 377,060 people. The Danish exposure-response curve was also non-linear rather than graded, which is difficult to reconcile with a simple dose effect and easier to explain by residual differences between municipalities.

Magnitude: Incidence rate ratio 0.83 (95% confidence interval 0.81–0.85) for dementia above 15 µg/L of water lithium versus 2–5 µg/L (an incidence rate ratio is the rate of new cases in one group divided by the rate in another); pooled relative risk 0.59 (0.44–0.78) for Alzheimer’s disease in one meta-analysis against an odds ratio of 0.94 (0.77–1.24) for dementia in another (relative risk is the simple ratio of event probabilities between groups).

Low 🟩

Lower Suicide Rates in Regions with Higher Water Lithium

Across dozens of ecological studies from Japan, Austria, Texas, Greece, England, and elsewhere, districts whose tap water carries more lithium tend to record fewer suicides. This is the largest body of evidence connecting trace lithium to a hard outcome, but it compares places rather than people, and Eyre-Watt et al., 2021 detected significant publication bias within it. A separate pooled analysis restricted to the same design reached a similar direction of effect (Barjasteh-Askari et al., 2020). No individual-level or interventional evidence supports the claim.

Magnitude: Pooled correlation of −0.19 (95% confidence interval −0.29 to −0.09) between water lithium concentration and regional suicide rate across 14 studies covering 94 million people.

Lower All-Cause Mortality with Trace Lithium Exposure ⚠️ Conflicted

This is the claim that most directly motivates longevity interest. Zarse et al., 2011 reported an inverse relationship between tap-water lithium and overall mortality across 18 neighboring Japanese municipalities totaling 1,206,174 people, and found that a comparable concentration extended lifespan in the roundworm Caenorhabditis elegans. Working against it, Mutz et al., 2024 examined 591 UK Biobank participants prescribed lithium and found no relationship between duration of use and telomere length (telomeres are the protective caps on chromosome ends that shorten with age), frailty, metabolomic age (an age estimate derived from the pattern of small molecules in blood), or all-cause mortality. The two studies address different exposures — trace environmental versus prescription — so they need not contradict each other, but together they mean the mortality signal is unreplicated in individual-level human data.

Magnitude: Regression coefficient −0.661 (a regression coefficient is the size and direction of the modelled change in one measure per unit change in another, so a negative value means mortality fell as lithium rose) for water lithium against all-cause mortality in the Japanese cohort, with a p-value of 0.003 (a p-value is the probability of seeing a result this extreme if there were truly no effect, so smaller means less likely to be chance); no measurable association across four aging markers in the UK Biobank analysis.

Mood and Anxiety Benefits at Sub-Therapeutic Doses

Interventional studies using serum levels at or below 0.6 mmol/L have reported benefit as an add-on treatment in depression and mania, with a safety record described as consistently good (Strawbridge et al., 2023). Survey data from 211 people buying lithium over the counter found cognition, anxiety, and mood the most commonly reported improvements (Strawbridge et al., 2025), though self-report from people who chose to take a supplement carries obvious expectation effects and the same survey found side effects and withdrawal phenomena more common than anticipated.

Magnitude: Not quantified in available studies.

Speculative 🟨

Lithium as a Required Trace Nutrient

The strongest version of the low-dose case is that lithium is a physiological requirement, that ordinary diets in many regions supply too little, and that repletion restores a lost protective function rather than adding a drug effect. The basis is one experimental line of work in mice and post-mortem human tissue, plus the observation that dietary lithium intake varies widely by geography. No human repletion trial has been conducted, no deficiency state has been clinically defined, no reference range for brain or serum lithium in healthy adults is established, and the authors of the review that treats the hypothesis most favorably note that it awaits independent replication.

Reduced Cellular Senescence and Slowed Biological Aging ⚠️ Conflicted

Microdose lithium reduced markers of cellular senescence (the state in which damaged cells stop dividing but keep emitting inflammatory signals) in cultured human astrocytes (the brain’s principal support cells) (Viel et al., 2020), and lithium extends lifespan in flies and worms through the antioxidant pathway described above. Human data are thin and inconsistent: one study found white blood cell telomeres longer with longer lithium treatment, another found no such relationship, and the UK Biobank analysis found none across several aging measures. The basis for this item is mechanistic and preclinical only.

Neuroprotection in Parkinson’s Disease and Motor Neuron Disease

Small early-phase trials are testing lithium against imaging and blood markers of neurodegeneration in Parkinson’s disease, and a pooled reanalysis of three completed trials in motor neuron disease (amyotrophic lateral sclerosis, the progressive and fatal degeneration of the nerves controlling movement) found that lithium improved 12-month survival specifically in carriers of one variant of UNC13A (a gene whose protein controls neurotransmitter release at nerve terminals), while showing no effect overall (van Eijk et al., 2017). That result was an exploratory subgroup analysis performed after the fact and has not been confirmed prospectively, so it functions as a hypothesis rather than a finding.

Benefit-Modifying Factors

UNC13A genotype: In the pooled motor neuron disease reanalysis, carriers of the risk variant of UNC13A (the gene encoding a protein that governs neurotransmitter release at nerve terminals) went from 40.1% to 69.7% 12-month survival on lithium, while non-carriers derived nothing. If this holds, lithium’s neurological benefit may be concentrated in genetically defined minorities rather than spread thinly across everyone.
Lithium-response genotypes: A variant in GADL1 (a gene encoding an enzyme involved in taurine synthesis) was associated with lithium response in a Han Chinese population but has not replicated in European samples. A genome-wide study by the International Consortium on Lithium Genetics identified a region on chromosome 21 associated with response, and a high polygenic score for schizophrenia (the summed effect of many small-effect gene variants) predicts poor lithium response. None of these is clinically actionable yet, and all were derived in bipolar cohorts rather than healthy ones.
APOE4 carriage: APOE4 (the variant of the apolipoprotein E gene that most strongly raises Alzheimer’s risk) is the best-characterised genetic determinant of who develops the disease. Carriers face a higher absolute risk of the outcome lithium is proposed to prevent, so the same relative effect would yield a larger absolute gain in this group. No trial has stratified lithium’s cognitive effect by APOE4 status, so this is an inference from baseline risk rather than a measured interaction.
Baseline lithium status and regional water content: If the trace-nutrient hypothesis is correct, benefit should concentrate in people whose habitual intake is low, and the drinking-water studies imply intake varies several-fold between regions. No validated assay for lithium sufficiency exists, so this cannot currently be measured in an individual.
Baseline neurodegenerative biomarkers: Effects in the mild cognitive impairment trials were seen on cerebrospinal fluid tau and on memory rather than on gross brain volume, which suggests benefit tracks the tau pathway more than the amyloid pathway. People with elevated phospho-tau but limited established brain shrinkage are the group in which the mechanism is most plausible, and the group these trials recruited.
Baseline kidney function and sodium intake: Both determine how much lithium a given dose delivers. Lower kidney filtration and lower sodium intake both raise lithium retention, meaning identical doses produce materially different exposures — and therefore different benefits — between individuals.
Sex-based differences: Lithium clearance is proportional to kidney filtration and lean mass, so women typically achieve higher serum levels than men on the same milligram dose and may reach the intended exposure at lower amounts. Randomized lithium trials in cognition have generally been underpowered to test whether the benefit itself differs by sex; the 2026 pilot trial was 56% female but did not report a sex interaction.
Pre-existing mood disorder: The largest and best-established benefits — relapse prevention and reduced suicide — exist only in people who already have a mood disorder. For everyone else, the entire case rests on the cognitive and mortality literature, which is weaker.
Age: Benefit is plausibly greatest in older adults because dementia risk rises steeply with age, so a given relative reduction yields more absolute benefit. This runs directly against the pharmacology: kidney filtration declines roughly 0.5–1 mL/min per year after age 40, so the same dose produces higher exposure and more side effects in exactly the group with most to gain. Every completed cognition trial recruited participants aged 60 and over.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Hypothyroidism and Goiter

Lithium concentrates in the thyroid and blocks the release of thyroid hormone, producing an underactive gland and sometimes a goiter (a visibly enlarged thyroid at the front of the neck). The evidence base is the pooled analysis of randomized placebo-controlled trials and cohort studies in the lithium toxicity meta-analysis, corroborated by prescribing information; the far rarer opposite reaction, lithium-associated hyperthyroidism, rests only on post-marketing reports. This is the most frequent clinically meaningful adverse effect of therapeutic lithium and the one most likely to be missed, because fatigue, weight gain, and mental slowing are easily attributed to aging. It is generally reversible on withdrawal and readily managed with thyroid hormone replacement without stopping lithium, and risk is concentrated in women and in people with pre-existing thyroid autoantibodies. Whether supplement-level doses carry any thyroid risk has not been formally studied.

Magnitude: Odds ratio 5.78 (95% confidence interval 2.00–16.67) for clinical hypothyroidism versus placebo, with mean thyroid-stimulating hormone elevated by 4.00 mIU/L.

Reduced Urinary Concentrating Ability

Lithium interferes with the kidney’s response to antidiuretic hormone (the hormone that instructs the kidney to conserve water), producing nephrogenic diabetes insipidus (an inability to concentrate urine that causes excessive urination and thirst, unrelated to diabetes mellitus despite the similar name). This is the earliest and most consistent renal effect of therapeutic lithium, appearing in a substantial minority within the first years and only partially reversible after long exposure. The quantification below comes from the pooled toxicity meta-analysis of 385 studies rather than from any single trial. Its practical danger is indirect: a person who cannot conserve water becomes dehydrated quickly during illness, heat, or hard exercise, and dehydration raises lithium levels, which worsens the defect.

Magnitude: A mean 15% reduction in maximum urinary concentrating ability (weighted mean difference −158 mOsm/kg, 95% confidence interval −230 to −87; a weighted mean difference is the average gap between groups across studies, with larger studies counted more heavily).

Hyperparathyroidism and Raised Blood Calcium

Lithium alters the calcium-sensing receptor on parathyroid cells, so the glands behave as though blood calcium were lower than it is and oversecrete parathyroid hormone (the hormone that pulls calcium out of bone). The consequences — bone loss, kidney stones, fatigue, mood change, and cognitive dulling — overlap almost perfectly with the symptoms lithium is being taken to prevent, which is why the toxicity meta-analysis specifically recommended checking calcium before and during treatment. A dedicated meta-analysis of this complication was published by Vandermeulen et al., 2024.

Magnitude: Mean increase of 0.09 mmol/L in blood calcium (95% confidence interval 0.02–0.17) and 7.32 pg/mL in parathyroid hormone (3.42–11.23) versus comparison groups.

Tremor

A fine, fast tremor of the hands is the most common visible effect of lithium and appears at ordinary therapeutic levels. It is dose-related, worse with caffeine, anxiety, and fine motor tasks, and usually improves with dose reduction, single evening dosing, or the addition of a beta-blocker (a class of medication that blunts the effect of adrenaline on the heart and nerves). The evidence is randomized placebo-controlled trial data at low dose together with prescribing information and pooled trial analyses at full therapeutic levels. A coarse tremor is different in kind and signals toxicity rather than a side effect.

Magnitude: Reported by 24% of participants on low-dose lithium versus 15% on placebo over two years in the 2026 pilot trial; substantially more frequent at full therapeutic levels.

Acute Toxicity from a Narrow Therapeutic Window

Lithium is among the few widely used medications whose toxic level sits immediately above its effective one, with no metabolic buffer between them, because the kidney is the only meaningful route of elimination. Anything that reduces kidney perfusion or sodium delivery — vomiting, diarrhea, fever, heat, a new diuretic, an anti-inflammatory, a very low-sodium diet — can push a stable level into the toxic range within days. Severe cases require hemodialysis (machine filtering of the blood), for which formal criteria exist (Decker et al., 2015). This risk applies to prescription dosing; supplement doses are two to three orders of magnitude below it, though poisoning from an internet-purchased lithium supplement has been reported (Pauzé & Brooks, 2007).

Magnitude: Serum levels above 1.5 mmol/L produce lethargy, weakness, and slurred speech; above 2.5 mmol/L, rigidity, confusion, seizures, arrhythmia, and death. The therapeutic target is 0.6–1.0 mmol/L.

Medium 🟥 🟥

Progressive Loss of Kidney Function ⚠️ Conflicted

Whether decades of lithium meaningfully damage the kidney is genuinely disputed. The toxicity meta-analysis found the average reduction in filtration rate small and not statistically significant, and end-stage kidney failure rare at 0.5% of 3,369 patients. Against that, Bocchetta et al., 2013 found duration of treatment an independent predictor of reduced filtration, and Van Alphen et al., 2021 documented ongoing decline in a treated cohort. The disagreement is partly one of framing: the average patient loses little, while a minority on very long exposure lose a great deal, and cohort averages conceal that minority.

Magnitude: Mean glomerular filtration rate reduction of 6.22 mL/min (95% confidence interval −14.65 to +2.20, not significant); 0.5% requiring renal replacement therapy across pooled cohorts.

Weight Gain

Lithium causes modest weight gain through a combination of increased thirst satisfied with caloric drinks, fluid retention, and thyroid suppression. The evidence base is the pooled analysis of randomized placebo-controlled trials in the lithium toxicity meta-analysis. Dose-independent peripheral edema of the ankles and wrists is described in prescribing information as a separate expression of the same fluid retention, and settles without stopping the drug. It is less pronounced than with most atypical antipsychotics (the newer class of medication used to treat psychosis and mania) but more than with placebo, and for anyone pursuing metabolic optimization it works against several other goals at once.

Magnitude: Odds ratio 1.89 (95% confidence interval 1.27–2.82) for weight gain versus placebo; typically 4–7 kg over the first year at therapeutic levels.

Gastrointestinal Effects

Nausea, loose stools, and diarrhea are common on starting lithium and usually settle within weeks. They matter beyond comfort because diarrhea causes sodium and fluid loss, which raises lithium levels, which worsens the diarrhea. The frequencies quoted come from randomized placebo-controlled trial data, and gastrointestinal upset is the most commonly reported early complaint in the prescribing information. Taking the dose with food and using an extended-release formulation both reduce the effect, though extended-release preparations shift more of the load to the lower bowel and can increase diarrhea specifically.

Magnitude: Diarrhea in 29% on lithium versus 15% on placebo over two years in the 2026 pilot trial.

Cognitive Dulling and Psychomotor Slowing ⚠️ Conflicted

A subjective flattening of mental sharpness, word-finding difficulty, and slowed reaction is among the most common reasons people stop lithium, and it is the effect most directly at odds with taking it for cognitive protection. Formal testing tends to find smaller deficits than patients report, concentrated in psychomotor speed and verbal memory, and effects are dose-related and largely reversible. A recent systematic review of lithium’s cognitive effects in humans found the literature mixed rather than uniformly negative (Sabtiari et al., 2025).

Magnitude: Not quantified in available studies.

Teratogenicity

First-trimester lithium exposure raises the risk of one birth defect in particular: Ebstein anomaly (a malformation in which the tricuspid valve of the heart is displaced). The relative risk for that specific defect is high because the baseline is extremely low, and its absolute risk remains small. The dedicated meta-analysis by Fornaro et al., 2020 pooled twenty-nine studies and found lithium in pregnancy associated with significantly higher odds of any congenital anomaly and of cardiac anomalies specifically, superseding the older toxicity meta-analysis, whose sparser pregnancy data had shown no significant overall increase. Both analyses nonetheless caution against reflexive withdrawal in pregnancy, because the relapse risk of stopping is itself substantial.

Magnitude: Odds ratio 1.81 (95% confidence interval 1.35–2.41) for any congenital anomaly and 1.86 (1.16–2.96) for cardiac anomalies with lithium in pregnancy; absolute risk of Ebstein anomaly of roughly 1 in 1,000 to 1 in 2,000 first-trimester exposures, against a background rate near 1 in 20,000.

Low 🟥

Dermatological Effects ⚠️ Conflicted

Acne, worsening of existing psoriasis, and diffuse hair thinning are frequently attributed to lithium in clinical practice and case series. The evidence is conflicted because the largest systematic synthesis recorded no significant increase in either hair loss or skin disorders relative to comparison groups, meaning the clinical impression and the pooled data disagree. Effects, when they occur, are generally reversible and dose-related.

Magnitude: No significant increase in hair loss or skin disorders in pooled analysis; individual case series report acne or psoriasis exacerbation in a minority of treated patients.

Cardiac Conduction Effects

Lithium commonly produces benign flattening or inversion of the T wave on an electrocardiogram (the standard tracing of the heart’s electrical activity), and rarely causes sinus node dysfunction (unreliable firing of the heart’s own pacemaker) or unmasks Brugada syndrome (an inherited electrical abnormality that predisposes to dangerous rhythms). The evidence here is electrocardiographic case series and post-marketing reports rather than controlled trials. Serious events are rare at therapeutic levels and mostly occur in toxicity or in people with pre-existing conduction disease.

Magnitude: Reversible electrocardiogram changes in roughly 20–30% of treated patients; clinically significant arrhythmia rare outside overdose.

Benign Leukocytosis

Lithium reliably produces leukocytosis (a raised white blood cell count), typically an increase in neutrophils, without infection. The effect is documented in observational hematology series and in the prescribing information rather than as a trial endpoint. It is harmless in itself and has occasionally been used therapeutically, but it confuses the interpretation of blood counts and can trigger unnecessary investigation if the cause is not known.

Magnitude: Typical increase of 2,000–5,000 white cells per microliter, reversing within days of stopping.

Sexual Dysfunction

Reduced desire, impaired arousal, and erectile difficulty are reported on therapeutic lithium, and sexual dysfunction appears in the prescribing information with no stated frequency. The proposed mechanisms are reduced dopamine signaling and interference with the nitric oxide pathway that produces erection, neither of which has been demonstrated in humans. The quantified evidence is a single uncontrolled cross-sectional study of 100 clinically stable people with bipolar disorder on long-term lithium, in which 37% met criteria for sexual dysfunction, more often among older participants and among those reporting other lithium side effects (Grover et al., 2014). Because that study had no lithium-free comparison group, the effect cannot be separated from the underlying mood disorder or from concurrent antidepressants, and nothing at all has been measured at supplement-level doses.

Magnitude: 37% prevalence among clinically stable bipolar patients on long-term therapeutic lithium in a single uncontrolled cross-sectional study; no placebo-controlled estimate exists.

Speculative 🟨

Contaminant and Potency Failures in Unregulated Supplements

Over-the-counter lithium is sold as a dietary supplement, so content and purity are not verified before sale. Independent testing has found products containing less lithium than labeled, and a 2025 recall removed underpotent lithium orotate products from the market. Heavy metal contamination is tested for by independent laboratories but not by regulators. The direct harm from this is undocumented — the failures found so far have been of underdosing rather than overdosing — so the concern is inferential rather than demonstrated.

Withdrawal Effects at Supplement Doses

Rebound mood destabilization after abrupt withdrawal of therapeutic lithium is well described. Whether anything comparable occurs after stopping trace doses is unknown; the only relevant data is a survey in which withdrawal phenomena were reported more often than the investigators expected, from a self-selected sample without any control group or blinding.

Long-Term Renal and Endocrine Effects of Trace Dosing

Every quantified renal, thyroid, and parathyroid risk in this section was measured at serum levels of 0.6 mmol/L and above. No cohort has followed people taking 1–5 mg of elemental lithium daily for the ten to thirty years over which those complications develop at higher doses. The absence of reported harm at trace doses reflects the absence of long-term observation as much as the absence of effect.

Risk-Modifying Factors

Absence of validated pharmacogenetic markers: No genetic variant is currently established as predicting lithium toxicity, and no pharmacogenetic test is clinically recommended before starting. Candidate work has examined variants in AQP2 (the gene encoding aquaporin-2, the water channel in the kidney collecting duct that lithium disables) as a possible determinant of who develops urinary concentrating failure, but nothing has replicated well enough to act on. Thyroid autoimmunity has a strong hereditary component and functions as the closest thing to a genetic risk marker in practice.
Baseline kidney function: Estimated glomerular filtration rate (the calculated measure of how fast the kidneys filter blood) is the single strongest determinant of lithium exposure and therefore of every dose-related harm. Below 60 mL/min/1.73 m², clearance falls enough that standard doses overshoot; below 30, lithium accumulates unpredictably.
Baseline thyroid and parathyroid status: Pre-existing elevated thyroid-stimulating hormone, positive thyroid peroxidase antibodies (thyroid peroxidase is the enzyme that attaches iodine to build thyroid hormone; antibodies against it mark autoimmune thyroid disease), or blood calcium in the upper reference range identify people who will cross into clinical disease sooner. These are cheap to measure and rarely checked before over-the-counter use.
Sodium status and habitual intake: The kidney reabsorbs lithium and sodium in competition, so anything that lowers sodium — a low-salt diet, heavy sweating, diuretic use — raises lithium retention. A person on a deliberately low-sodium regimen carries a materially higher risk at the same dose. Chronically high sodium intake has the opposite effect and lowers levels.
Sex-based differences: Women carry substantially higher risk of both lithium-associated hypothyroidism and hyperparathyroidism, in line with the underlying sex distribution of those diseases, and reach higher serum levels per milligram because of lower lean mass and filtration rate. Pregnancy adds the teratogenic risk above, and lithium clearance rises sharply during pregnancy then falls abruptly at delivery, a swing that has caused post-partum toxicity.
Pre-existing conditions: Heart failure, cirrhosis, and any state of reduced effective circulating volume increase lithium reabsorption. Existing thyroid disease, hyperparathyroidism, kidney stones, psoriasis, and Brugada syndrome each amplify a specific lithium harm. Conditions causing recurrent vomiting or diarrhea create repeated episodes of acute risk.
Age: Older adults have lower kidney filtration, a longer lithium half-life, greater sensitivity to neurological effects at any given serum level, more concurrent medications that interact, and a higher likelihood of dehydration from intercurrent illness. Therapeutic targets in people over 65 are typically set 25–50% lower than in younger adults for these reasons, and the same logic argues for caution at the upper end of supplement dosing.

Key Interactions & Contraindications

Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) — caution, dose reduction required: Thiazide diuretics (a class of blood-pressure medication that makes the kidney excrete more salt and water) deplete sodium and increase proximal reabsorption of lithium, raising serum levels by roughly 25–40% and precipitating toxicity. If unavoidable, lithium dose is typically cut by a quarter to a half and the level rechecked within 5–7 days.
ACE inhibitors and ARBs (lisinopril, ramipril, losartan, valsartan) — caution, monitor: ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin receptor blockers) are two classes of blood-pressure medication that both reduce kidney perfusion pressure, raising lithium levels by up to about 35%, with older adults most affected. A serum lithium level 1–2 weeks after starting or changing either drug detects the rise.
NSAIDs (ibuprofen, naproxen, diclofenac, celecoxib) — caution, generally avoid: NSAIDs (nonsteroidal anti-inflammatory drugs) block prostaglandins (local signaling molecules that keep blood flowing through the kidney) and can raise lithium levels by 15–60% within days, a common cause of unintentional toxicity because they are bought without prescription. Paracetamol/acetaminophen and topical anti-inflammatories are the standard substitutions; if an NSAID is genuinely required, a level after 5–7 days is the mitigation.
Loop diuretics (furosemide, bumetanide) and acetazolamide — monitor: Loop diuretics (a more potent class of diuretic acting on a different part of the kidney) have a smaller and more variable effect on lithium than thiazides but still warrant a level check. Acetazolamide moves the other way and increases lithium excretion, which can cause loss of effect.
SSRIs and other serotonergic drugs (sertraline, fluoxetine, venlafaxine, tramadol, triptans) — caution: SSRIs (selective serotonin reuptake inhibitors, the most common class of antidepressant) combined with lithium can produce serotonin syndrome (a dangerous excess of serotonin signaling causing agitation, fever, rigidity, and rapid heart rate). The combination is used deliberately and safely in psychiatry but requires awareness of the presentation.
Antipsychotics (haloperidol, risperidone, olanzapine) — caution: Case reports describe an encephalopathic syndrome (acute brain dysfunction) with confusion, rigidity, fever, and raised muscle enzymes when lithium is combined with high-potency antipsychotics, particularly at higher lithium levels. Keeping the lithium level at the lower end of range is the standard mitigation.
Sodium bicarbonate, sodium-containing antacids, and high-sodium electrolyte products — monitor: Increase lithium excretion and can cause loss of effect. Relevant to anyone using sodium-loaded electrolyte formulations around training.
Caffeine and theophylline — monitor: Both increase renal lithium clearance; caffeine can lower lithium levels by roughly 20–25%. The practical hazard runs in the reverse direction — abruptly ending a high habitual caffeine intake can raise levels — and caffeine independently worsens lithium tremor.
Iodine and kelp supplements — caution, additive effect: Add to lithium’s thyroid suppression, since both interfere with thyroid hormone release. This is the clearest example of a supplement with an additive effect on a lithium harm; separating them does not help, and thyroid monitoring or avoidance is the mitigation.
Serotonergic supplements (St. John’s wort, 5-HTP, SAMe, high-dose tryptophan) — caution, additive effect: Combine with lithium’s own serotonergic action in the same direction as the antidepressant interaction above, with the same syndrome as the consequence. 5-HTP (5-hydroxytryptophan, the direct building block the body converts into serotonin) and SAMe (S-adenosylmethionine, a methyl-donor molecule sold for mood support) act on serotonin availability most directly of the four.
Psyllium and other bulk fiber supplements — monitor: Reduce lithium absorption when taken together. Separating administration by at least two hours resolves it.
Creatine, sodium bicarbonate loading, and other fluid-shifting ergogenic aids — monitor: Ergogenic aids (supplements taken to improve athletic performance) of this type alter total body water and sodium handling, changing lithium distribution unpredictably. Relevant mainly to anyone combining lithium with athletic supplementation.
Sauna, heat exposure, and prolonged endurance exercise — caution: Not drugs, but the most common real-world cause of lithium level excursions in an otherwise healthy, active person. Sodium and water loss through sweat concentrates lithium; deliberate heat protocols and long training sessions require replacement of both.
Populations who should avoid lithium: Anyone with an estimated glomerular filtration rate below 30 mL/min/1.73 m² (avoid; 30–59 requires specialist dose reduction and close monitoring); pregnancy during weeks 2–8 of gestation, when cardiac formation occurs; untreated or unstable hypothyroidism; documented primary hyperparathyroidism or blood calcium above 2.60 mmol/L; Brugada syndrome or a family history of unexplained sudden cardiac death; sick sinus syndrome (a disorder in which the heart’s natural pacemaker fires unreliably); New York Heart Association Class III–IV heart failure; severe dehydration or any condition causing ongoing sodium loss; a deliberately sodium-restricted diet below about 2 g of sodium daily; and anyone unable or unwilling to have blood monitoring at therapeutic doses.

Risk Mitigation Strategies

Minimum trace starting dose held for 4–8 weeks: Protocols that begin at 1 mg of elemental lithium daily, rather than the 5 mg many products supply in a single unit, and hold that amount for 4–8 weeks before any increase, limit exposure over the window in which the earliest adverse effects — tremor, gastrointestinal upset, mental dulling — would declare themselves. This mitigates dose-related side effects and the risk of overshooting in someone with unrecognized reduced kidney clearance.
Pre-treatment kidney, thyroid, and calcium baselines: Estimated glomerular filtration rate, thyroid-stimulating hormone, and serum calcium measured before the first dose mitigate the three highest-ranked harms by making any later change detectable. Without a baseline, a thyroid-stimulating hormone of 4.2 mIU/L two years into treatment is uninterpretable.
Steady sodium and fluid intake: Fluid intake held at roughly 2–3 L daily, with no deliberate sodium restriction, prevents the increased lithium reabsorption that drives toxicity. Consistency matters more than absolute quantity, because it is the change in sodium intake that shifts the level.
Sick-day rules agreed in advance: Withholding lithium during vomiting, diarrhea, fever above 38.5 °C, or any illness limiting fluid intake, and resuming once eating and drinking are normal, addresses the single most common route to acute toxicity. At therapeutic doses this plan is normally agreed with the prescriber ahead of time rather than improvised during illness.
Paracetamol in place of anti-inflammatories: Substituting paracetamol/acetaminophen for ibuprofen and naproxen in routine pain relief removes the most frequent unintentional cause of raised lithium levels. Where an anti-inflammatory is unavoidable, a serum lithium level 5–7 days after starting it detects the rise before symptoms appear.
Once-daily evening dosing with food: Single evening dosing produces a lower 24-hour renal exposure than the same amount divided across the day and has been associated with less urinary concentrating impairment, while food reduces nausea. This mitigates both the renal and the gastrointestinal harms and moves peak-related tremor into sleeping hours.
Label verification against elemental content: Lithium is only about 4% of lithium orotate by mass, so a product listing “5 mg lithium orotate” delivers roughly 0.2 mg of lithium while one listing “5 mg lithium (as orotate)” delivers twenty-five times more. Confirming which figure a label states prevents both accidental overdosing and a dose too small to do anything.
Third-party tested products only: Products carrying USP, NSF, or independent laboratory verification mitigate the contamination and potency risks that follow from lithium supplements being unregulated before sale, including the underpotency that triggered a 2025 market recall.
Twelve-hour trough level at prescription doses: Prescription-level use is monitored with serum lithium drawn exactly 12 hours after the last dose, 5–7 days after any dose change and every 3–6 months thereafter, because the toxic threshold sits directly above the therapeutic one. Levels drawn at other intervals are not interpretable against the standard range and give false reassurance.
Fixed-schedule thyroid and calcium testing: Thyroid-stimulating hormone and serum calcium measured at 6 and 12 months and annually thereafter, rather than in response to symptoms, catch hypothyroidism and hyperparathyroidism before they produce complaints that would be misread as aging or as the cognitive decline lithium was taken to prevent.
Dose reduction rather than escalation when cognition worsens: Because lithium can cause the exact symptom it is taken to avert, treating a decline in mental sharpness as grounds for a higher dose inverts the appropriate response. A dose reduction or a supervised withdrawal trial distinguishes a drug effect from disease progression.

Therapeutic Protocol

Three distinct approaches, not one: Lithium use for health and longevity splits into three protocols that share only the molecule. Trace or nutritional dosing supplies 1–5 mg of elemental lithium daily, usually as orotate, without blood monitoring. Sub-therapeutic prescription dosing uses lithium carbonate titrated to a serum level of 0.25–0.5 mmol/L. Conventional therapeutic dosing targets 0.6–1.0 mmol/L and is reserved for mood disorders. No head-to-head comparison exists between any two of these, so the choice currently rests on which risk profile a person is willing to accept rather than on demonstrated superiority.
Trace-dose protocol: 1–5 mg of elemental lithium once daily, most commonly taken in the evening. This is the approach used in integrative practice, promoted historically by Hans Nieper, who introduced lithium orotate in the 1970s, and more recently associated with the integrative psychiatrist James Greenblatt, who has written a book on nutritional lithium. Supporting human evidence is a single small trial of 300 µg daily in Alzheimer’s disease (Nunes et al., 2013) plus survey and mechanistic data.
Sub-therapeutic prescription protocol: Lithium carbonate 150–300 mg daily, titrated against serum level to 0.25–0.5 mmol/L. This is the protocol developed by Orestes Forlenza’s group at the University of São Paulo and used in both of their mild cognitive impairment trials. It requires a prescriber and blood monitoring but sits well below the level at which most renal and endocrine harm accumulates.
Low-dose trial protocol: The LATTICE trial run by Ariel Gildengers at the University of Pittsburgh started lithium carbonate at 150 mg daily and titrated to a steady serum level of 0.6–0.8 mmol/L over two years. It is worth distinguishing from the São Paulo approach because its target sits within the conventional psychiatric range despite being labeled low-dose, and its adverse-event rates reflect that.
Time of day: Evening dosing is standard. It places the peak concentration during sleep, which reduces the visibility of tremor and daytime mental dulling, and allows a 12-hour trough level to be drawn the following morning without disrupting the schedule.
Half-life and its consequences: With an elimination half-life of 18–36 hours, steady state is reached in about 5 days, which sets the earliest sensible interval for a confirmatory level after any dose change. The same half-life means a single missed dose has little effect, and that a level rising because of dehydration or a new medication takes several days to become dangerous rather than hours.
Single versus divided dosing: Once-daily dosing is preferred at every dose level. It produces the same total exposure with a longer daily trough, and the trough — not the peak — is what determines renal injury, so single dosing has been associated with less urinary concentrating impairment than the same amount split across the day. Divided dosing is used only when gastrointestinal upset is intolerable.
Genetic considerations for dose choice: No pharmacogenetic test currently guides lithium dosing. The variants discussed above — GADL1, the chromosome 21 locus identified by the International Consortium on Lithium Genetics, and the schizophrenia polygenic score — predict response in bipolar cohorts but have neither replicated broadly nor been tested in non-psychiatric use. APOE4 status and UNC13A genotype affect who might benefit rather than what dose to use.
Sex-based dose differences: Women typically reach a given serum level on a lower milligram dose than men because of lower lean mass and kidney filtration rate, so titration by level rather than by dose is important. Lithium clearance approximately doubles during pregnancy and returns to baseline within days of delivery, requiring dose changes in both directions around that window.
Age-related dose adjustment: Because kidney filtration declines with age, adults over 65 typically need 25–50% less lithium to reach the same serum level, and are more sensitive to neurological effects at any given level. Both cognition trials recruited only people aged 60 and over, so the dosing evidence in this population is comparatively better than in younger adults.
Baseline biomarkers influencing response: Baseline estimated glomerular filtration rate determines the dose needed for a given exposure. Baseline thyroid-stimulating hormone, calcium, and sodium intake determine tolerability. Baseline cerebrospinal fluid or plasma phospho-tau plausibly identifies who has the pathology the mechanism targets, though no protocol currently selects on it.
Pre-existing conditions influencing response: An established mood disorder is the only condition in which the response to lithium is reliably predictable. Reduced kidney function, heart failure, and thyroid disease all shift the dose-exposure and dose-harm relationships rather than the benefit, meaning they change how lithium is given rather than whether it works.

Discontinuation & Cycling

Intended duration: For the mood-disorder indication, lithium is a lifelong treatment, and this is where the strongest evidence sits. For cognitive and longevity purposes it is implicitly also lifelong: the population data associate benefit with cumulative decades of exposure, the mild cognitive impairment trials ran for two to four years and found effects emerging over years rather than months, and no protocol has ever defined a completion point. Anyone starting for this purpose is starting something without a described end.
Withdrawal effects at therapeutic doses: Abrupt discontinuation of therapeutic lithium in bipolar disorder causes rebound mania at a rate exceeding the baseline relapse risk, an effect specific to rapid withdrawal rather than to being off lithium. This is one of the better-documented discontinuation syndromes in psychiatry and is the main argument against stopping lithium quickly for any reason short of toxicity.
Withdrawal effects at supplement doses: Not established. The only relevant human data is a survey of 211 over-the-counter users in which withdrawal phenomena were reported more frequently than the investigators anticipated, without a control group, blinding, or verification of what participants had actually been taking.
Tapering protocol: Where lithium is being stopped rather than urgently withdrawn, reduction over a minimum of 2–4 weeks, and preferably over 3 months, substantially reduces rebound risk compared with immediate cessation. In toxicity the drug is stopped outright and the taper question does not arise.
Cycling: No evidence supports cycling lithium, and no tolerance or receptor downregulation has been described that cycling would counteract. A theoretical argument exists for intermittent dosing to reduce cumulative renal exposure, but it has never been tested, and the mechanisms proposed for cognitive protection — accumulation in brain tissue, sustained enzyme inhibition, chronic neurotrophic signaling — all depend on continuous exposure, so intermittent use may forfeit the benefit while retaining much of the risk.

Sourcing and Quality

Prescription versus supplement forms: Prescription lithium is supplied as lithium carbonate or lithium citrate in 150, 300, and 600 mg strengths of the compound. Over-the-counter lithium is supplied as lithium orotate, lithium aspartate, or ionic lithium solutions, in amounts one to three orders of magnitude smaller. All forms deliver the same lithium ion; whether the orotate salt behaves differently after absorption is actively disputed, as set out in Mechanism of Action.
Elemental content is the only meaningful number: Lithium is roughly 4% of lithium orotate and roughly 19% of lithium carbonate by mass. Labels are inconsistent about which they state, and the difference between “5 mg lithium orotate” and “5 mg lithium as orotate” is twenty-five-fold. Independent testing has specifically flagged this labeling ambiguity as misleading to buyers.
Third-party testing: Because dietary supplements are not verified for content or purity before sale, USP Verified, NSF Certified for Sport, or independent laboratory certification is the only practical assurance. The relevant tests are lithium content against label and screening for lead, cadmium, and arsenic. A 2025 recall of lithium orotate products for underpotency demonstrates that the failure mode is real rather than hypothetical.
Reputable suppliers: Independently tested lithium orotate products from established supplement manufacturers that publish certificates of analysis are the practical option; ConsumerLab named three products as top picks in its most recent testing round. For sub-therapeutic prescription dosing, standard pharmacy lithium carbonate is preferable to any supplement because content is verified by regulation, and a compounding pharmacy can prepare intermediate strengths where the commercial 150 mg capsule is too large a step.
Formulation choice at prescription doses: Immediate-release lithium carbonate produces a higher peak and more nausea; extended-release produces a flatter curve but delivers more lithium to the lower bowel and can worsen diarrhea. Neither is uniformly superior, and switching between them changes the serum level enough to warrant rechecking it.
Water and dietary sources: Lithium intake from food and water ranges from well under 100 µg to more than 3 mg daily depending on region, with grains, vegetables, and mineral waters the main contributors. Some mineral waters carry more lithium than a low-dose supplement, which is worth accounting for before adding one.

Practical Considerations

Time to effect: Nothing in this domain is fast. Mood stabilization at therapeutic doses takes 1–3 weeks. The cognitive endpoints in the trials that found anything separated from placebo over 12–24 months, and the population data associate benefit with decades of exposure. Anyone expecting a subjective change from a trace dose within weeks is measuring the wrong thing on the wrong timescale — the one exception being side effects, which appear early.
Common pitfalls: Confusing compound weight with elemental lithium content, and so taking twenty-five times more or less than intended. Assuming that an over-the-counter designation implies no interactions, when anti-inflammatories, blood-pressure medications, and diuretics all affect lithium regardless of dose. Skipping baseline thyroid and kidney measurements because the dose seems trivial. Restricting sodium and taking lithium simultaneously. Increasing the dose in response to mental dulling that the lithium itself is causing. And extrapolating benefits demonstrated at 0.6–1.0 mmol/L to doses that produce serum levels a hundred times lower.
Regulatory status: Lithium carbonate and citrate are prescription medications approved for bipolar disorder; every use discussed in this review for cognition, longevity, or general health is off-label. Low-dose lithium is sold legally as a dietary supplement in the United States under the Dietary Supplement Health and Education Act, with no pre-market approval of safety, content, or claims. Several jurisdictions, including the United Kingdom and much of the European Union, classify lithium as a medicine at any dose and do not permit its sale as a supplement, so availability varies substantially by country.
Cost and accessibility: Lithium is among the least expensive interventions in this field. Generic lithium carbonate costs a few dollars a month, and lithium orotate supplements typically run under twenty dollars for several months’ supply. The cost of the associated monitoring at prescription doses — periodic serum lithium, kidney, thyroid, and calcium testing — exceeds the cost of the drug several times over. This inexpensiveness has a second-order consequence: lithium cannot be patented, so no commercial sponsor has an incentive to fund the large trials that would resolve its status, and the trials that exist have been small, academic, and publicly funded.

Interaction with Foundational Habits

Sleep — direct, bidirectional: Lithium lengthens the circadian period and delays sleep phase, an effect attributed to GSK-3β regulation of the PER2 clock protein, and it suppresses rapid-eye-movement sleep (the dreaming stage). In practice it tends to consolidate sleep in people whose sleep is disrupted by mood instability and to shift sleep later in people whose sleep is already stable. Evening dosing works with this rather than against it. Daytime sedation, when it occurs, usually reflects a peak concentration that arrives too early, and moving the dose later addresses it.
Nutrition — direct and consequential: Sodium intake is not a peripheral consideration but a direct determinant of lithium exposure, because the kidney handles the two ions in competition. Ketogenic diets (very low carbohydrate, high fat, so the body burns fat for fuel), carnivore diets, and other low-carbohydrate patterns cause a natriuresis (increased sodium excretion) in the first weeks, which lowers body sodium and can raise lithium levels; the same applies to prolonged fasting. Iodine-rich foods and kelp add to lithium’s thyroid suppression. On the other side, dietary lithium itself varies several-fold with the mineral content of local water and produce, which is worth accounting for before supplementing. The practical pattern is consistency: sodium and fluid intake held steady, rather than optimized independently of the lithium regimen.
Exercise — indirect, potentiating the risk rather than the benefit: Lithium has no documented effect on hypertrophy (muscle growth in response to training), endurance adaptation, or recovery, so it neither helps nor blunts training. The interaction runs entirely through fluid and electrolyte loss: a long ride, a hot race, or a hard sauna session after training can lose enough sodium and water to raise a stable lithium level into an unwelcome range. Replacing both during and after prolonged or hot sessions is the mitigation, and lithium tremor is more noticeable in fine motor tasks and in the shaking hands that follow heavy exertion.
Stress management — indirect, potentiating the benefit: Lithium dampens stress-induced glutamate signaling and moderates hypothalamic-pituitary-adrenal axis activity (the hormonal chain running from brain to adrenal glands that produces cortisol), which is one proposed contributor to its neuroprotective effect, since chronically elevated cortisol is itself associated with hippocampal shrinkage. Stress-reduction practices act on the same pathway from the other end and are complementary rather than redundant. The practical caution is that heat-based stress protocols, sauna in particular, interact with lithium through sweat losses as described above.

Monitoring Protocol & Defining Success

Before starting lithium at any dose, a baseline panel establishes both eligibility and the reference point against which every later result is judged. At minimum this means kidney function, thyroid function, and serum calcium, because these are the three organ systems lithium acts on most reliably; body weight and an electrocardiogram are added where prescription dosing is planned or where cardiac history warrants it. The reason for baseline testing is not primarily to detect a contraindication — most people have none — but to make later change interpretable, since a single out-of-range value years into treatment cannot be attributed to lithium without knowing where the person started.

Ongoing monitoring cadence depends on dose. At therapeutic or sub-therapeutic prescription doses: serum lithium 5–7 days after initiation and after every dose change, then every 3 months for the first year and every 3–6 months thereafter, with kidney, thyroid, and calcium panels at 3 months, 6 months, 12 months, and annually. At trace supplement doses, serum lithium is not measurable in any clinically useful way and is not worth drawing; kidney, thyroid, and calcium panels every 12 months are proportionate, moving to 6-monthly if any value drifts.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum lithium, 12-hour trough	0.25–0.5 mmol/L for cognitive protocols; 0.6–1.0 mmol/L for mood; undetectable on trace doses	The only direct measure of exposure; toxicity begins just above the therapeutic range	Drawn exactly 12 hours after the last dose — samples taken at other intervals are uninterpretable. Not worth measuring below about 1 mg elemental lithium daily
Estimated glomerular filtration rate	>90 mL/min/1.73 m²; a fall of more than 25% from baseline warrants investigation	Determines lithium clearance and therefore exposure at any given dose	The calculated measure of how fast the kidneys filter blood. Conventional reporting calls anything above 60 mL/min/1.73 m² normal, so a drop from 100 to 70 passes as unremarkable while being exactly the change that matters on lithium. The creatinine-based version overestimates function in people with high muscle mass, so cystatin C is paired with it where muscle mass is unusual. Fasting not required
Cystatin C	0.6–1.0 mg/L	Kidney filtration marker independent of muscle mass; more reliable than creatinine in very muscular or very low-muscle individuals	Best paired with the creatinine-based filtration estimate; a large gap between the two indicates one of them is misleading
Urine osmolality, first morning	>600 mOsm/kg	Detects loss of urinary concentrating ability, the earliest renal effect of lithium	A measure of how concentrated the urine is. Requires overnight water restriction to interpret. Below 300 mOsm/kg with high urine volume suggests nephrogenic diabetes insipidus
Thyroid-stimulating hormone	0.5–2.0 mIU/L	Detects the most common lithium-associated endocrine effect before symptoms appear	Conventional reference ranges extend to 4.0–4.5 mIU/L, so a result reported as normal can conceal a clear upward shift from baseline. Drawn in the morning, since levels fall through the day
Free T4	1.0–1.5 ng/dL, upper half of the reference range	Distinguishes mild from overt hypothyroidism when thyroid-stimulating hormone rises	The unbound, active fraction of the main thyroid hormone. Best drawn on the same sample as thyroid-stimulating hormone. Biotin supplements distort the assay and are stopped 48 hours beforehand
Thyroid peroxidase antibodies	Negative	Identifies before starting who is most likely to become hypothyroid on lithium	Markers of autoimmune thyroid disease. Measured once at baseline rather than serially; a positive result argues for 6-monthly rather than annual thyroid testing
Serum calcium, albumin-corrected	2.20–2.45 mmol/L	Detects lithium-associated hyperparathyroidism, whose symptoms mimic the cognitive decline lithium is taken to prevent	Corrected for albumin or measured as ionized calcium, since total calcium alone misleads. Conventional ranges extend to 2.60 mmol/L, which is too permissive on lithium
Parathyroid hormone	15–45 pg/mL	Confirms the mechanism when calcium rises; can be elevated before calcium leaves the reference range	The hormone that raises blood calcium by drawing it from bone. Drawn simultaneously with calcium, since either value alone is uninterpretable. Fasting morning sample preferred
Serum sodium	138–142 mmol/L	Low sodium raises lithium retention; also screens for the dilutional effect of excessive water intake	Conventional reference ranges run 135–145 mmol/L, so a result of 136 is reported as normal while it already signals increased lithium retention. Paired with the lithium level on the same draw. A falling sodium alongside a rising lithium level is the classic toxicity pattern
Complete blood count	Within reference range, with a modest expected rise in neutrophils	Lithium reliably causes a benign white cell rise that would otherwise prompt an infection workup	The on-treatment baseline is established at 3 months so the elevation is subsequently recognized as expected rather than investigated
Body weight	Stable within 2 kg of baseline	Weight gain is one of the more common reasons for discontinuation and may signal thyroid suppression	Interpreted alongside thyroid-stimulating hormone before gain is attributed to lithium directly
Plasma phospho-tau 217	Below the assay’s positivity threshold; the trajectory matters more than any single value	The most practical blood measure of the pathology lithium’s proposed mechanism targets	A blood marker of the tau protein tangles found in Alzheimer’s disease. Thresholds are laboratory-specific and not interchangeable, so the same laboratory is used each time. Emerging rather than established as a monitoring tool
Neurofilament light chain	Age-adjusted; a rising value over time is the signal	Non-specific marker of ongoing neuronal injury, used as a secondary endpoint in current lithium trials	A protein released into blood when nerve cells are damaged. Rises with age and with reduced kidney filtration, so interpreted alongside the filtration estimate. Research-grade rather than routine

Qualitative markers matter more here than in most protocols, because the intended benefit — a decline that does not happen — is invisible, while several of the harms become subjectively obvious long before any laboratory value moves.

Mental sharpness and word-finding: The most informative subjective marker, because lithium can either protect or dull cognition and the person taking it notices first which of the two is happening. A consistent sense of slowed thinking or of reaching for words points toward dose reduction rather than escalation.
Tremor: A fine tremor appearing when holding a cup or writing is the earliest visible sign of excess. Its appearance or worsening tracks dose and caffeine intake closely.
Thirst and urine volume: A new need to drink constantly, or repeated waking at night to urinate, is the clinical face of lost urinary concentrating ability, and is the trigger for a urine osmolality measurement rather than a matter of hydration discipline.
Energy, mood, and cold tolerance: Fatigue, low mood, and new cold intolerance are how lithium-induced hypothyroidism presents, and they are easily misattributed to aging or to the season.
Sleep quality and timing: Whether sleep is consolidating or drifting later is worth recording, since lithium acts on the circadian clock and the direction of that effect varies between individuals.
Gastrointestinal tolerance: Persistent loose stools are both a side effect in their own right and a mechanism of toxicity through sodium loss, which makes them a signal to act on rather than something to acclimatize to.

Emerging Research

LATTICE: The first controlled test of lithium against imaging endpoints in mild cognitive impairment. NCT03185208, 83 randomized, Phase 4, University of Pittsburgh with the National Institute on Aging, completed August 2024 and published as Gildengers et al., 2026. None of six co-primary endpoints reached significance. Its lasting contribution is the effect-size estimate: the verbal memory difference of 0.69 points per year defines how large a trial would have to be to settle the question, and that number is considerably larger than anything currently funded.
LiO-AD — the first trial of lithium orotate specifically: NCT07459959, 40 participants, Phase 1/2, Johns Hopkins University, starting October 2026 with completion projected for 2029. This is the direct clinical test of the salt-selection question raised by the 2025 lithium-deficiency work, with feasibility, safety, renal and thyroid endpoints, and biomarker engagement. If orotate proves to be simply a lithium ion after absorption, as chemists have argued, the supplement market’s entire premise loses its distinguishing claim.
Lithium for prevention of cognitive decline in mood illness: NCT06662526, 250 participants, Phase 4, University of Chile, with incidence of mild cognitive impairment as the primary endpoint and completion projected for 2030. Its enrollment is three times that of LATTICE, and its design tests prevention of a clinical event rather than change on a cognitive scale, which is the more meaningful question and the harder one to answer.
Lithium in Parkinson’s disease: NCT06339034 and its extension NCT06592014, 20 and 35 participants, Phase 1/2, State University of New York at Buffalo. Primary endpoints are imaging-derived brain free water (a scan measure of fluid outside cells, which rises as tissue degenerates) and serum neurofilament light chain rather than symptoms, an approach designed to detect biological effect in samples far too small to detect clinical benefit. A recent overview of this direction is Boonstra, 2026.
Lithium against radiotherapy-induced cognitive impairment: NCT06051240, 84 participants, Phase 2, Region Stockholm, running to 2033 with processing speed as the primary endpoint. Its participants are survivors of childhood brain tumors irradiated before age 18, so it speaks to the mechanism rather than to anyone in this review’s audience. Because radiation injury has a known onset date, this design can detect a protective effect on a timescale that spontaneous neurodegeneration does not allow.
The lithium-deficiency hypothesis and its replication: Aron et al., 2025 is the finding most likely to change how lithium is understood, and it is currently unreplicated. Independent measurement of brain lithium across other post-mortem cohorts, and independent testing of whether amyloid sequesters lithium, would either establish a new class of intervention or remove the mechanistic foundation of the low-dose case. The counter-argument on the chemistry has already been published as Hajek et al., 2026.
Whether a measurable lithium status exists: Brain lithium can now be quantified non-invasively at supplement doses (Neal et al., 2024), which opens the possibility of identifying who is actually deficient rather than dosing everyone alike. If no reproducible deficiency state can be defined, the nutrient framing collapses regardless of what the mouse data show.
Evidence that could weaken the case: Three specific results would do so. A larger replication of the null dementia association found by Huang et al., 2024 would suggest the protective signal is confounding by indication. Long-term renal or parathyroid follow-up of trace-dose users showing the same harms seen at therapeutic doses would remove the safety argument for supplementation. And failure to replicate the brain lithium depletion finding would leave the low-dose case resting on ecological correlations with documented publication bias.
The structural problem behind all of it: Every trial listed here enrolls between 20 and 250 people and is funded by a university, a national institute, or a philanthropic foundation. The comparator interventions in this disease area — anti-amyloid antibodies costing tens of thousands of dollars per patient per year — have been tested in trials of one to two thousand participants funded by their manufacturers. Lithium cannot be patented, so no equivalent sponsor exists. Insurers and national health systems have the opposite incentive and would benefit substantially from a cheap alternative, but they fund almost no primary drug research. The result is not that lithium has been tested and found wanting; it is that lithium has been tested at a fraction of the scale applied to its expensive competitors, and small trials produce inconclusive answers by construction.

Conclusion

Lithium occupies an unusual position. It is unmistakably a drug at high doses, arguably a nutrient at very low ones, and cheap enough at both that it attracts no commercial sponsor. That funding gap is part of the evidence picture rather than separate from it. Where money flows — toward patent-protected memory treatments costing tens of thousands a year — the studies are large and conclusive; lithium’s are small and are not. Much of the enthusiastic writing about the low-dose version also comes from companies that sell it, and the cautious writing often comes from a field with its own long-standing view of the substance.

What the evidence supports firmly is narrow. At prescription strength, lithium prevents the return of severe mood episodes and reduces deaths among people who have them. The wider claims — a slower slide into memory loss, fewer dementia diagnoses, longer life where the water carries more of it — rest on comparisons between populations and on small studies that point in encouraging directions without agreeing with one another. The harms at prescription strength are well documented and center on the thyroid, the kidneys, and calcium handling. At the tiny amounts sold over the counter those harms appear rare, though nobody has watched anyone take them for thirty years. The distance between what is plausible here and what is established remains wide.

Top - Benefits - Risks - Protocol

Lithium for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Prevention of Recurrence in Bipolar Disorder

Reduced Suicide and All-Cause Death in Mood Disorders

Medium 🟩 🟩

Slower Cognitive Decline in Mild Cognitive Impairment ⚠️ Conflicted

Lower Dementia Incidence with Long-Term Exposure ⚠️ Conflicted

Low 🟩

Lower Suicide Rates in Regions with Higher Water Lithium

Lower All-Cause Mortality with Trace Lithium Exposure ⚠️ Conflicted

Mood and Anxiety Benefits at Sub-Therapeutic Doses

Speculative 🟨

Lithium as a Required Trace Nutrient

Reduced Cellular Senescence and Slowed Biological Aging ⚠️ Conflicted

Neuroprotection in Parkinson’s Disease and Motor Neuron Disease

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Hypothyroidism and Goiter

Reduced Urinary Concentrating Ability

Hyperparathyroidism and Raised Blood Calcium

Tremor

Acute Toxicity from a Narrow Therapeutic Window

Medium 🟥 🟥

Progressive Loss of Kidney Function ⚠️ Conflicted

Weight Gain

Gastrointestinal Effects

Cognitive Dulling and Psychomotor Slowing ⚠️ Conflicted

Teratogenicity

Low 🟥

Dermatological Effects ⚠️ Conflicted

Cardiac Conduction Effects

Benign Leukocytosis

Sexual Dysfunction

Speculative 🟨

Contaminant and Potency Failures in Unregulated Supplements

Withdrawal Effects at Supplement Doses

Long-Term Renal and Endocrine Effects of Trace Dosing

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion